DailyDoctor Archive Specialties Get app
Back to the 16 September 2026 edition

Research · 05 of 07

Pilocarpine drops did not beat placebo for dry mouth in frail patients, in an underpowered trial

For dry mouth in frail patients, start with medication review and mouth care; pilocarpine drops are an option without proven benefit.

Design
Double-blind, placebo-controlled randomised trial, 5 Dutch sites
Population
92 adults with xerostomia and a life-limiting condition or frailty
Primary outcome
Change in xerostomia severity (NRS 0-10) at 4 weeks
Effect
Adjusted β -0.37 (95% CI -1.31 to 0.58), not significant

This double-blind randomised trial at two Dutch hospitals and three nursing homes enrolled 92 adults with a life-limiting condition or frailty and xerostomia rated 5 or more out of 10, allocating them to four weeks of topical pilocarpine drops or placebo.

There was no significant difference in xerostomia severity at two weeks (adjusted β 0.35, 95% CI -0.44 to 1.15) or four weeks (β -0.37, -1.31 to 0.58). Both groups improved by about 1.5 points in the first two weeks; only the pilocarpine group continued to improve to week four. Oral health quality of life was better with pilocarpine at two weeks. Side effects were limited.

Dry mouth is a common and neglected symptom in frail and dying patients, with few treatment options. The trial recruited 92 of the 120 needed, so it could have missed a real effect.

Pilocarpine drops remain a reasonable trial for a distressed patient, but not one backed by evidence of benefit.

  • Review anticholinergic and other drying medications first.
  • Use simple measures: sips of water, saliva substitutes, mouth care.
  • Pilocarpine drops can be tried, with realistic expectations.
  • Watch for sweating and bradycardia with any pilocarpine use.

Why it matters

A symptom that affects comfort at the end of life still lacks a proven drug treatment.

Don't overread it

The trial enrolled 92 of 120 planned participants, so a lack of significant difference does not prove pilocarpine is ineffective.

The statistics, in plain English

An underpowered trial is too small to detect the effect it was designed to find. The intervals for the primary outcome include both small benefit and small harm, and the late improvement seen only with pilocarpine is a within-group finding, weaker than a between-group comparison.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

QR code to install Daily Doctor
Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.

fallshealthyageingdeprescribingbonehealthgerifrailtypalliative

Tomorrow morning, before your first patient

One edition a day for geriatrics, written by the desk, every claim tied to its paper. Six minutes.

Get the app — free
Daily Doctor All 27 specialties, every morning. Free.
Get the app